Merck says experimental skin disease drug meets main goal in mid-stage study
MRK•Merck said its experimental drug met the main goal of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa, a chronic skin disease.
1. Study result
Merck said its experimental drug met the main goal of a mid-stage study in patients with moderate-to-severe hidradenitis suppurativa, which causes painful lumps, abscesses and scarring.
